Mast Therapeutics, Inc.
15
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
20.0%
3 terminated/withdrawn out of 15 trials
76.9%
-9.6% vs industry average
27%
4 trials in Phase 3/4
20%
2 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis
Role: collaborator
Study of the Effect of Renal Impairment on the Pharmacokinetics of Vepoloxamer
Role: lead
Evaluation of Vepoloxamer in Chronic Heart Failure
Role: lead
Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)
Role: lead
Evaluation of Repeat Administration of Purified Poloxamer 188
Role: lead
Evaluation of MST-188 in Acute Lower Limb Ischemia
Role: lead
ANX-188 Thorough QT/QTc Study in Healthy Volunteers
Role: lead
Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease
Role: lead
A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer.
Role: lead
A Clinical Trial of CoFactor Formulations and Leucovorin Administered Intravenously in Healthy, Adult Subjects.
Role: lead
A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
Role: lead
Clinical Trial in Patients With Metastatic Colorectal Cancer
Role: lead
5-Fluorouracil Combined With CoFactor (5-10 Methylenetetrahydrofolate) in Treating Advanced Breast Cancer Patients
Role: lead
Clinical Trial in Patients With Metastatic Colorectal Cancer
Role: lead
Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.
Role: lead
All 15 trials loaded